Bajaj Finserv Healthcare Fund Regular Growth
EquitySector - HealthcareVery High Risk
Regular
NAV (17-Apr-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹307 Cr
Expense Ratio
2.36%
ISIN
INF0QA701987
Minimum SIP
₹100
Exit Load
1.00%
Inception Date
27 Dec 2024
About this fund
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹9.21, Assets Under Management (AUM) of 307.40 Crores, and an expense ratio of 2.36%.
- Bajaj Finserv Healthcare Fund Regular Growth has given a CAGR return of -7.91% since inception.
- The fund's asset allocation comprises around 92.05% in equities, 0.00% in debts, and 7.95% in cash & cash equivalents.
- You can start investing in Bajaj Finserv Healthcare Fund Regular Growth with a SIP of ₹100 or a Lumpsum investment of ₹500.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-7.91%
— (Cat Avg.)
Portfolio Summaryas of 31st March 2025
| Equity | ₹282.96 Cr | 92.05% |
| Others | ₹24.44 Cr | 7.95% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Divi's Laboratories Ltd | Equity | ₹27.3 Cr | 8.88% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹25.96 Cr | 8.44% |
| Dr Reddy's Laboratories Ltd | Equity | ₹24.29 Cr | 7.90% |
| Cipla Ltd | Equity | ₹24.05 Cr | 7.82% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹16.94 Cr | 5.51% |
| Net Receivables / (Payables) | Cash | ₹14.62 Cr | 4.76% |
| Biocon Ltd | Equity | ₹12.05 Cr | 3.92% |
| Piramal Pharma Ltd | Equity | ₹11.59 Cr | 3.77% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹9.82 Cr | 3.19% |
| Syngene International Ltd | Equity | ₹9.55 Cr | 3.11% |
| Neuland Laboratories Limited | Equity | ₹8.47 Cr | 2.76% |
| Torrent Pharmaceuticals Ltd | Equity | ₹7.9 Cr | 2.57% |
| Emcure Pharmaceuticals Ltd | Equity | ₹7.63 Cr | 2.48% |
| Ipca Laboratories Ltd | Equity | ₹7.58 Cr | 2.47% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹6.5 Cr | 2.11% |
| Rainbow Childrens Medicare Ltd | Equity | ₹6.44 Cr | 2.09% |
| Hindustan Unilever Ltd | Equity | ₹6.43 Cr | 2.09% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹6.22 Cr | 2.02% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹6.11 Cr | 1.99% |
| Abbott India Ltd | Equity | ₹6.01 Cr | 1.95% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹5.73 Cr | 1.86% |
| Dr. Reddy's Laboratories Limited April 2025 Future | Equity - Future | ₹-5.65 Cr | 1.84% |
| Zydus Wellness Ltd | Equity | ₹5.36 Cr | 1.74% |
| Orchid Pharma Ltd | Equity | ₹5.17 Cr | 1.68% |
| Pfizer Ltd | Equity | ₹5.14 Cr | 1.67% |
| Alkem Laboratories Ltd | Equity | ₹4.66 Cr | 1.52% |
| Emami Ltd | Equity | ₹4.37 Cr | 1.42% |
| Lupin Ltd | Equity | ₹3.97 Cr | 1.29% |
| AstraZeneca Pharma India Ltd | Equity | ₹3.91 Cr | 1.27% |
| Alembic Pharmaceuticals Ltd | Equity | ₹3.71 Cr | 1.21% |
| Dr. Lal PathLabs Ltd | Equity | ₹3.59 Cr | 1.17% |
| Mankind Pharma Ltd | Equity | ₹3.52 Cr | 1.15% |
| Marico Ltd | Equity | ₹3.45 Cr | 1.12% |
| Medplus Health Services Ltd | Equity | ₹3.37 Cr | 1.10% |
| Jubilant Pharmova Ltd | Equity | ₹3.13 Cr | 1.02% |
| Medi Assist Healthcare Services Ltd | Equity | ₹2.87 Cr | 0.93% |
| Colgate-Palmolive (India) Ltd | Equity | ₹2.68 Cr | 0.87% |
| Shaily Engineering Plastics Ltd | Equity | ₹1.79 Cr | 0.58% |
| Neogen Chemicals Ltd | Equity | ₹1.14 Cr | 0.37% |
Allocation By Market Cap (Equity)
Large Cap Stocks
37.71%
Mid Cap Stocks
27.05%
Small Cap Stocks
26.37%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹254.91 Cr | 82.93% |
| Consumer Defensive | ₹22.29 Cr | 7.25% |
| Basic Materials | ₹2.93 Cr | 0.95% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Fund Managers
Nimesh Chandan
Since December 2024
Siddharth Chaudhary
Since December 2024
Sorbh Gupta
Since December 2024
Additional Scheme Detailsas of 31st March 2025
ISIN INF0QA701987 | Expense Ratio 2.36% | Exit Load 1.00% | Fund Size ₹307 Cr | Age 3 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
| Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
| PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
| PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
| WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
| WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
| DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
| Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
| Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
| HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Risk Level
Your principal amount will be at Very High Risk
Take control of your wealth
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Bajaj Finserv Healthcare Fund Regular Growth?
What is the portfolio composition of Bajaj Finserv Healthcare Fund Regular Growth?
Who manages the Bajaj Finserv Healthcare Fund Regular Growth?
- Nimesh Chandan
- Siddharth Chaudhary
- Sorbh Gupta
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Bajaj Finserv Healthcare Fund Regular Growth
EquitySector - HealthcareVery High Risk
Regular
NAV (17-Apr-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹307 Cr
Expense Ratio
2.36%
ISIN
INF0QA701987
Minimum SIP
₹100
Exit Load
1.00%
Inception Date
27 Dec 2024
Risk Level
Your principal amount will be at Very High Risk
About this fund
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹9.21, Assets Under Management (AUM) of 307.40 Crores, and an expense ratio of 2.36%.
- Bajaj Finserv Healthcare Fund Regular Growth has given a CAGR return of -7.91% since inception.
- The fund's asset allocation comprises around 92.05% in equities, 0.00% in debts, and 7.95% in cash & cash equivalents.
- You can start investing in Bajaj Finserv Healthcare Fund Regular Growth with a SIP of ₹100 or a Lumpsum investment of ₹500.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-7.91%
— (Cat Avg.)
Portfolio Summaryas of 31st March 2025
| Equity | ₹282.96 Cr | 92.05% |
| Others | ₹24.44 Cr | 7.95% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Divi's Laboratories Ltd | Equity | ₹27.3 Cr | 8.88% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹25.96 Cr | 8.44% |
| Dr Reddy's Laboratories Ltd | Equity | ₹24.29 Cr | 7.90% |
| Cipla Ltd | Equity | ₹24.05 Cr | 7.82% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹16.94 Cr | 5.51% |
| Net Receivables / (Payables) | Cash | ₹14.62 Cr | 4.76% |
| Biocon Ltd | Equity | ₹12.05 Cr | 3.92% |
| Piramal Pharma Ltd | Equity | ₹11.59 Cr | 3.77% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹9.82 Cr | 3.19% |
| Syngene International Ltd | Equity | ₹9.55 Cr | 3.11% |
| Neuland Laboratories Limited | Equity | ₹8.47 Cr | 2.76% |
| Torrent Pharmaceuticals Ltd | Equity | ₹7.9 Cr | 2.57% |
| Emcure Pharmaceuticals Ltd | Equity | ₹7.63 Cr | 2.48% |
| Ipca Laboratories Ltd | Equity | ₹7.58 Cr | 2.47% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹6.5 Cr | 2.11% |
| Rainbow Childrens Medicare Ltd | Equity | ₹6.44 Cr | 2.09% |
| Hindustan Unilever Ltd | Equity | ₹6.43 Cr | 2.09% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹6.22 Cr | 2.02% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹6.11 Cr | 1.99% |
| Abbott India Ltd | Equity | ₹6.01 Cr | 1.95% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹5.73 Cr | 1.86% |
| Dr. Reddy's Laboratories Limited April 2025 Future | Equity - Future | ₹-5.65 Cr | 1.84% |
| Zydus Wellness Ltd | Equity | ₹5.36 Cr | 1.74% |
| Orchid Pharma Ltd | Equity | ₹5.17 Cr | 1.68% |
| Pfizer Ltd | Equity | ₹5.14 Cr | 1.67% |
| Alkem Laboratories Ltd | Equity | ₹4.66 Cr | 1.52% |
| Emami Ltd | Equity | ₹4.37 Cr | 1.42% |
| Lupin Ltd | Equity | ₹3.97 Cr | 1.29% |
| AstraZeneca Pharma India Ltd | Equity | ₹3.91 Cr | 1.27% |
| Alembic Pharmaceuticals Ltd | Equity | ₹3.71 Cr | 1.21% |
| Dr. Lal PathLabs Ltd | Equity | ₹3.59 Cr | 1.17% |
| Mankind Pharma Ltd | Equity | ₹3.52 Cr | 1.15% |
| Marico Ltd | Equity | ₹3.45 Cr | 1.12% |
| Medplus Health Services Ltd | Equity | ₹3.37 Cr | 1.10% |
| Jubilant Pharmova Ltd | Equity | ₹3.13 Cr | 1.02% |
| Medi Assist Healthcare Services Ltd | Equity | ₹2.87 Cr | 0.93% |
| Colgate-Palmolive (India) Ltd | Equity | ₹2.68 Cr | 0.87% |
| Shaily Engineering Plastics Ltd | Equity | ₹1.79 Cr | 0.58% |
| Neogen Chemicals Ltd | Equity | ₹1.14 Cr | 0.37% |
Allocation By Market Cap (Equity)
Large Cap Stocks
37.71%
Mid Cap Stocks
27.05%
Small Cap Stocks
26.37%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹254.91 Cr | 82.93% |
| Consumer Defensive | ₹22.29 Cr | 7.25% |
| Basic Materials | ₹2.93 Cr | 0.95% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Fund Managers
Nimesh Chandan
Since December 2024
Siddharth Chaudhary
Since December 2024
Sorbh Gupta
Since December 2024
Additional Scheme Detailsas of 31st March 2025
ISIN INF0QA701987 | Expense Ratio 2.36% | Exit Load 1.00% | Fund Size ₹307 Cr | Age 3 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
|---|---|---|---|---|
| Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
| Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
| PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
| PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
| WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
| WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
| DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
| Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
| Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
| HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Bajaj Finserv Healthcare Fund Regular Growth?
What is the portfolio composition of Bajaj Finserv Healthcare Fund Regular Growth?
Who manages the Bajaj Finserv Healthcare Fund Regular Growth?
- Nimesh Chandan
- Siddharth Chaudhary
- Sorbh Gupta
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
Track all you investments in one place
Download Wealth Monitor App
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Get your portfolio reviewed by experts
